Rapid development of drug resistance during initial dolutegravir-based antiretroviral therapy of an infant with HIV
Dolutegravir resistance is predominantly reported in antiretroviral therapy-experienced individuals. We describe an infant who developed high-level resistance to abacavir, lamivudine, and dolutegravir within 97 days of initiation, despite initial wild-type infection. Causative factors likely include probable sub-therapeutic antiretroviral drug levels, poor tolerance, severe immunocompromise, and a high pre-treatment viral load.
Authors
- Natasha O’Connell (ORCID: https://orcid.org/0009-0002-6445-2973)
- Stephen N.J. Korsman (ORCID: https://orcid.org/0000-0002-1667-4363)
- Gert Uves van Zyl (ORCID: https://orcid.org/0000-0003-3021-5101)
- James Nuttall (ORCID: https://orcid.org/0000-0002-9389-5880)
- Tara-Lee von Mollendorff (ORCID: https://orcid.org/0000-0001-5788-8686)
Institutions
- National Health Laboratory Service (ZA)
- University of Cape Town (ZA)
- Stellenbosch University (ZA)
- Groote Schuur Hospital (ZA)
Publication Details
- Journal
- Southern African Journal of HIV Medicine
- Published
- 2025-10-09
- DOI
- https://doi.org/10.4102/sajhivmed.v26i1.1750
- Citations
- 1
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.40